ReviewWorld journal of diabetes2023
Diabetes mellitus and atrial fibrillation-from pathophysiology to treatment.
Review in World journal of diabetes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Dietary interventions in the management of atrial fibrillation.Frontiers in cardiovascular medicine · 2024Pooled it
- Impact of Non-Vitamin K Antagonist Oral Anticoagulants on Cardiovascular Outcomes in Diabetes Patients with Atrial Fibrillation: A Single-Center Experience.Acta Cardiologica Sinica · 2026Article
- Understanding the Diseased Atria.Physiology (Bethesda, Md.) · 2026Review
- Extracellular Vesicles as Mediators of Pathophysiology and Disease Progression in Cardiovascular Diseases.International journal of molecular sciences · 2026Review
- Comparative cardiovascular outcomes of GLP-1 receptor agonists vs. SGLT2 inhibitors in type 2 diabetes: a large-scale real-world cohort analysis.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Clinical and Echocardiographic Predictors of New-Onset Atrial Fibrillation in Patients with Non-AF Arrhythmias: An Exploratory Analysis of NT-proBNP.Biomedicines · 2026Article
- Left ventricular wall motion abnormalities in transfusion-dependent thalassemia: A large cross-sectional cardiovascular magnetic resonance study.The international journal of cardiovascular imaging · 2026Article
- Left Atrial Strain as a Marker of Supraventricular Arrhythmia Risk in Type 2 Diabetes Mellitus.Diseases (Basel, Switzerland) · 2026Article
- Cardiometabolic index predicts postoperative atrial fibrillation after isolated CABG: ROC-based comparison with BMI and visceral adiposity indices.Biomolecules & biomedicine · 2026Article
- Therapeutic efficacy and safety profile of SGLT-2 inhibitor dapagliflozin in heart failure with reduced and preserved ejection fraction: a systematic review and meta-analysis.Annals of medicine and surgery (2012) · 2025Article
- Hypertension and Diabetes as Determinants of Patient-Reported Quality of Life in Permanent Atrial Fibrillation.Diagnostics (Basel, Switzerland) · 2025Article
- Metformin and Risk of New-Onset Atrial Fibrillation in Type 2 Diabetes: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2025Review
- The Impact of Weight Categories on the Association Between Atrial Fibrillation/Flutter and Known Risk Factors: A Nationwide Inpatient Data Analysis.Journal of clinical medicine · 2025Article
- Exploring Anti-Inflammatory Treatment as Upstream Therapy in the Management of Atrial Fibrillation.Journal of clinical medicine · 2025Review
- Mechanisms of beneficial effects of DPP-4 inhibitors as a promising perspective for the prevention/treatment of the disruption of cardio-cerebrovascular homeostasis.Frontiers in pharmacology · 2025Review
- Type 2 diabetes mellitus and cardiovascular health: Evidence of causal relationships in a European ancestry population.ESC heart failure · 2024Article
- From a Cup of Tea to Cardiovascular Care: Vascular Mechanisms of Action.Life (Basel, Switzerland) · 2024Review
- Evaluating left atrial function changes by speckle tracking echocardiography in type 2 diabetes patients in Central Vietnam: a cross-sectional comparative study.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2024Article
- Risk and Protective Factors of Recurrence after Catheter Ablation for Atrial Fibrillation.Reviews in cardiovascular medicine · 2024Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes mellitus (T2DM) is a leading risk factor for cardiovascular complications around the globe and one of the most common medical conditions. Atrial fibrillation (AF) is the most common supraventricular arrhythmia, with a rapidly increasing prevalence. T2DM has been closely associated with the risk of AF development, identified as an independent risk factor. Regarding cardio-vascular complications, both AF and T2DM have been linked with high mortality. The underlying pathophysiology has not been fully determined yet; however, it is multifactorial, including structural, electrical, and autonomic pathways. Novel therapies include pharmaceutical agents in sodium-glucose cotransporter-2 inhibitors, as well as antiarrhythmic strategies, such as cardioversion and ablation. Of interest, glucose-lowering therapies may affect the prevalence of AF. This review presents the current evidence regarding the connection between the two entities, the pathophysiological pathways that link them, and the therapeutic options that exist.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.